Evaluating Two Radiation Treatments for Brain Cancer and Their Effects on Memory
NCT04804644 · RecruitingThis trial looks at two ways to treat brain cancer caused by small cell lung cancer. One method is called stereotactic radiosurgery, which delivers a strong dose of radiation directly to the tumor. The other method is whole brain radiation therapy that avoids a part of the brain important for memory, called the hippocampus. The main goal is to see which treatment better helps patients keep their memory and thinking skills.
Locations and contact
This trial is running at 227 locations. The first 8 are listed here.
- Mayo Clinic Hospital in ArizonaPhoenix, ArizonaActive, not recruiting
- Kaiser Permanente-AnaheimAnaheim, CaliforniaRecruiting
- Kaiser Permanente-BellflowerBellflower, CaliforniaRecruiting
- Kaiser Permanente Los Angeles Medical CenterLos Angeles, CaliforniaRecruiting
- Los Angeles General Medical CenterLos Angeles, CaliforniaRecruiting
- USC / Norris Comprehensive Cancer CenterLos Angeles, CaliforniaRecruiting
- Kaiser Permanente-OntarioOntario, CaliforniaRecruiting
- UCHealth University of Colorado HospitalAurora, ColoradoActive, not recruiting
Who can join
Adults aged 18 and older can join this trial. It is open to both men and women with a confirmed diagnosis of small cell lung cancer that has spread to the brain. Participants should have brain tumors that are 4 cm or smaller and meet other specific health criteria. The trial team will confirm who is eligible to participate.
What happens during the trial
Participants are randomly placed into one of two groups. One group receives stereotactic radiosurgery, while the other group undergoes whole brain radiation therapy along with a medication called memantine. Everyone will also have blood samples taken and MRIs done during the study to monitor their progress.
The trial team
The trial is sponsored by NRG Oncology, with support from the National Cancer Institute. Vinai Gondi is the principal investigator leading the study.
Important dates
This trial started on June 8, 2021, and is actively recruiting new participants. It is expected to finish by July 1, 2030, with primary results expected by July 1, 2028.
Additional information
The trial's ID number is NCT04804644. It is a Phase 3 trial, meaning it is looking at how well the treatments work and how safe they are. The trial aims to include about 200 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →